Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Cancer Cachexia Market From 2025 To 2029?

In recent times, there has been a robust growth in the cancer cachexia market size. It is projected to rise from $2.47 billion in 2024 to $2.62 billion in 2025, showcasing a compound annual growth rate (CAGR) of 6.4%. The growth over the historic period could be ascribed to enhanced knowledge of cancer biology, rising cancer prevalence, an escalading elderly population, increased emphasis on patient-centered care, wider range of treatment options, and heightened awareness amongst healthcare providers.

What Is the Projected Market Size of the Cancer Cachexia Market?

The market for cancer cachexia is projected to experience robust expansion in the upcoming years, reaching $3.33 billion by 2029 with a 6.2% compound annual growth rate (CAGR). The projected growth within this forecast period may be due to a heightened understanding of cachexia management, a burgeoning aging population, increased acceptance of innovative therapeutic methods, rising healthcare expense, and supportive government policies. Major occurrences predicted for this period encompass escalating research and development activities, broadening therapeutic alternatives, enhanced rates of diagnoses, implementation of groundbreaking treatment modalities, and advancements in support care tactics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

Who are the Major Competitors in the Cancer Cachexia Market Outlook?

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

What Is Fueling Growth in the Cancer Cachexia Market?

The swell in cancer incidences is anticipated to stimulate the expansion of the cancer cachexia market. Cancer encompasses a condition in which abnormal cells grow rampantly in the body, constructing tumors and obstructing ordinary body functions. The rise in cancer cases is credited to various constituents, inclusive of lifestyle alterations, environmental elements, an aging populace, genetic predisposition, refined diagnostic procedures resulting in earlier identification, and heightened awareness, thereby encouraging more individuals to pursue medicinal care. Gains in medical technology and a heightened comprehension of cancer and its complications are contributing to more frequent discoveries and documentation of cancer cachexia. Healthcare practitioners are enhancing their skill to distinguish cachexia symptoms, enabling precocious interventions and the initiation of treatment. For instance, in December 2023, as per the Australian Bureau of Statistics, a government agency based in Australia for national statistics, approximately 1.8% of the populace, or 456,200 people, were stated to have cancer in Australia in 2022. Also, in May 2024, as per the National Cancer Institute, a Federal government agency based in the U.S., in 2024, an expected 2,001,140 new cases of cancer will be diagnosed in the U.S., with predictions of 611,720 deaths from the disease. In 2022, approximately 20 million new cases globally and 9.7 million cancer-related deaths transpired. By 2040, the quantity of new cancer cases yearly is anticipated to jump to 29.9 million and cancer-related deaths to 15.3 million. Consequently, the escalating prevalence of cancer is fueling the growth of the cancer cachexia market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

Which Cancer Cachexia Market Segments Are Growing the Fastest?

The cancer cachexia market covered in this report is segmented –

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate, Medroxyprogesterone Acetate, Hydroxyprogesterone Caproate

2) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids, Progestogens + Anabolic Agents, Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents, Appetite Stimulants, Anti-inflammatory Drugs, Nutritional Supplements

Which Industry Trends Are Shaping the Future of the Cancer Cachexia Market?

Leading firms in the cancer cachexia market are focusing on the creation of novel treatments such as monoclonal antibodies for cachexia, with the goal of producing a precise therapy for cancer cachexia and enhancing the body weight, muscle bulk, and overall life quality of the afflicted patients. A cachexia-specific monoclonal antibody functions by targeting and suppressing factors that contribute to weight and muscle loss. For example, Pfizer Inc., an American pharmaceutical corporation, revealed promising results of its Phase 2 trial for Ponsegromab, a GDF-15-targeting monoclonal antibody, in cancer cachexia patients, in September 2024. This study demonstrated a marked body weight increase and improvements in muscle bulk, appetite, and physical activity levels, with the 400mg dose yielding the most powerful results. Based on these encouraging outcomes, Pfizer intends to commence registration-enabling studies in 2025 to further explore Ponsegromab’s efficacy in treating cancer cachexia.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Which Countries Are Leading the Cancer Cachexia Market?

North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15527

This Report Delivers Insight On:

1. How big is the cancer cachexia market, and how is it changing globally?

2. Who are the major companies in the cancer cachexia market, and how are they performing?

3. What are the key opportunities and risks in the cancer cachexia market right now?

4. Which products or customer segments are growing the most in the cancer cachexia market?

5. What factors are helping or slowing down the growth of the cancer cachexia market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model